Request Demo
Cabaletta Bio to Join Stifel 2024 Virtual Cell Therapy Forum
15 July 2024
PHILADELPHIA, July 02, 2024 — Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company, has made an announcement regarding their upcoming participation in a significant industry event. Steven Nichtberger, M.D., Chief Executive Officer of Cabaletta Bio, will be featured in a fireside chat at the Stifel 2024 Virtual Cell Therapy Forum on Tuesday, July 9, 2024, at 1:00 p.m. ET.
The company has arranged for a live webcast of the presentation, which will be accessible on the News and Events section of their website. Additionally, replays of the presentation will be available on the website for a period of 30 days, allowing for extended access to the information shared during the forum.
Cabaletta Bio is dedicated to the discovery and development of engineered T cell therapies. These therapies aim to provide long-lasting and potentially curative treatments for patients suffering from autoimmune diseases. The company's platform, referred to as CABA™, includes two primary strategies: CARTA and CAART.
The CARTA strategy features CABA-201, a fully human CD19-CAR T cell containing the 4-1BB co-stimulatory domain, as its leading product candidate. CABA-201 is currently being evaluated through the RESET™ clinical trials, which are focused on diseases such as systemic lupus erythematosus, myositis, systemic sclerosis, and generalized myasthenia gravis. Additionally, the RESET-PV™ sub-study within the DesCAARTes™ clinical trial is focused on pemphigus vulgaris.
The CAART strategy involves the development of chimeric autoantibody receptor T cells, with several candidates in the clinical stage. These include DSG3-CAART, aimed at treating mucosal pemphigus vulgaris, and MuSK-CAART, targeting MuSK-associated myasthenia gravis. Cabaletta Bio’s expanding platform is designed to create therapies that offer profound and lasting responses for a broad spectrum of autoimmune diseases.
Cabaletta Bio's headquarters and laboratories are situated in Philadelphia, PA. The company's efforts are focused on generating innovative solutions that could transform the treatment landscape for patients with autoimmune conditions.
The company has arranged for a live webcast of the presentation, which will be accessible on the News and Events section of their website. Additionally, replays of the presentation will be available on the website for a period of 30 days, allowing for extended access to the information shared during the forum.
Cabaletta Bio is dedicated to the discovery and development of engineered T cell therapies. These therapies aim to provide long-lasting and potentially curative treatments for patients suffering from autoimmune diseases. The company's platform, referred to as CABA™, includes two primary strategies: CARTA and CAART.
The CARTA strategy features CABA-201, a fully human CD19-CAR T cell containing the 4-1BB co-stimulatory domain, as its leading product candidate. CABA-201 is currently being evaluated through the RESET™ clinical trials, which are focused on diseases such as systemic lupus erythematosus, myositis, systemic sclerosis, and generalized myasthenia gravis. Additionally, the RESET-PV™ sub-study within the DesCAARTes™ clinical trial is focused on pemphigus vulgaris.
The CAART strategy involves the development of chimeric autoantibody receptor T cells, with several candidates in the clinical stage. These include DSG3-CAART, aimed at treating mucosal pemphigus vulgaris, and MuSK-CAART, targeting MuSK-associated myasthenia gravis. Cabaletta Bio’s expanding platform is designed to create therapies that offer profound and lasting responses for a broad spectrum of autoimmune diseases.
Cabaletta Bio's headquarters and laboratories are situated in Philadelphia, PA. The company's efforts are focused on generating innovative solutions that could transform the treatment landscape for patients with autoimmune conditions.
How to obtain the latest research advancements in the field of biopharmaceuticals?
In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.